Combined interferon--antimetabolite therapy of murine L1210 leukemia.
To assess the interaction of interferon with estabished chemotherapeutic agents, L1210 murine leukemia in BDF/1 mice was treated with methotrexate, 6-mercaptopurine. Adriamycin, cytosine arabinoside or cyclophosphamide alone or in combination with mouse L-cell (Newcastle disease virus-induced) interferon or with interferon-free tissue culture medium. Also studied was the effect of interferon on the combined 6-mercaptopurine-methotrexate therapy of this tumor. Interferon failed to enhance the response of L1210 leukemia to 6-mercaptopurine, adriamycin, cytosine arabinoside or cyclophosphamide. The addition of interferon to all methotrexate-containing regimens increased mean survival time (P less than 0.05). The increase in survival of host animals treated with 6-mercaptopurine-methotrexate and interferon was sustained though four transfer generations despite evolving resistance to this antimetabolite combination.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D007372:Interferons / Q000008:administration & dosage*; D007939:Leukemia L1210 / Q000628:therapy*; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D051379:Mice; D008811:Mice, Inbred DBA; D011379:Prognosis
D000970:Antineoplastic Agents; D003561:Cytarabine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007372:Interferons; D015122:Mercaptopurine; D008727:Methotrexate